Natera stock falls 5.80 percent after hitting a yearly high

Published on 10/06/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock traded at USD 400.97 on October 6, 2026, after reaching a USD 437.41 intraday high. Q2 revenue rose 37.7 percent to USD 752.75 million, while consensus remains Moderate Buy.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera stock (ISIN US6323071042) was last at USD 400.97 on Nasdaq on October 6, 2026, down USD 24.67, or 5.80 percent, from the prior close of USD 425.64. The intraday high reached USD 437.41, matching the current 52-week high, while the stock's intraday low stood at USD 394.77.

A sharp reversal from the high

The price action gives Natera a two-sided market profile: the stock touched its yearly peak before trading materially lower during the session. Its 52-week range runs from USD 167.33 to USD 437.41, leaving the latest quotation USD 36.44 below the high and USD 233.64 above the low.

MarketBeat reported on October 6, 2026, that Natera reached a new 52-week high and cited an average analyst target of USD 341.55. The market capitalization stood at USD 57.4 billion based on the October 6 quotation.

Quarterly growth beats estimates

Natera's latest reported quarter was Q2 2026, ended June 30, 2026. According to MarketBeat on October 6, 2026, revenue increased 37.7 percent year over year to USD 752.75 million, compared with analysts' USD 661.24 million estimate. The company reported a loss of USD 0.47 per share, narrower than the USD 0.49 consensus loss.

The figures show why operating growth remains central to the Natera story even as the share price trades near its yearly peak. The revenue comparison is particularly important because the quarterly result combined a 37.7 percent year-over-year increase with a 13.8 percent beat against the published revenue estimate.

Regulatory expansion adds support

On September 22, 2026, Natera said its Signatera test received Japanese regulatory approval as a companion diagnostic for muscle-invasive bladder cancer. The company expects a commercial launch in the first half of 2027, pending approval of atezolizumab and final reimbursement and pricing decisions, according to Natera.

Consensus trails the quotation

MarketBeat said on October 6, 2026, that 23 analysts supported a Moderate Buy consensus, with an average price target of USD 341.55. The target sits below the USD 400.97 quotation, making valuation and execution the key counterweights to the company's revenue growth and regulatory progress.